Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Gross Margin for 4 consecutive years, with 96.67% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 1558.0% year-over-year to 96.67%, compared with a TTM value of 81.63% through Sep 2025, down 117.0%, and an annual FY2024 reading of 83.71%, up 8736.0% over the prior year.
  • Gross Margin was 96.67% for Q3 2025 at Atara Biotherapeutics, roughly flat from 96.85% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q4 2022 and bottomed at 265.07% in Q2 2023.
  • Average Gross Margin over 4 years is 44.39%, with a median of 81.73% recorded in 2023.
  • The sharpest move saw Gross Margin plummeted -6481bps in 2023, then skyrocketed 34891bps in 2024.
  • Year by year, Gross Margin stood at 100.0% in 2022, then crashed by -65bps to 35.19% in 2023, then surged by 125bps to 79.25% in 2024, then increased by 22bps to 96.67% in 2025.
  • Business Quant data shows Gross Margin for ATRA at 96.67% in Q3 2025, 96.85% in Q2 2025, and 79.18% in Q1 2025.